Skip to main content

Cardiovascular Risk Factors

0
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
European Study of Cardiovascular RiskN/A1 trial
Management of Cardiovascular Risk FactorsN/A1 trial
Active Trials
NCT00882336Completed7,200Est. Oct 2009
NCT00848380Completed1,492Est. Dec 2009
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Dietary and nutritional modificationN/A1 trial
Active Trials
NCT00486993Completed18,287Est. Jul 2014
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
VolunteeringN/A1 trial
Active Trials
NCT01698034CompletedEst. Jan 2012
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Worksite health promotion programN/A1 trial
Active Trials
NCT04686812Completed2,002Est. Jun 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
T-TherapeuticsVolunteering
Angeles TherapeuticsWorksite health promotion program
AstraZenecaEuropean Study of Cardiovascular Risk
AstraZenecaManagement of Cardiovascular Risk Factors
Heidelberg PharmaDietary and nutritional modification

Clinical Trials (5)

Total enrollment: 28,981 patients across 5 trials

NCT01698034T-TherapeuticsVolunteering

Volunteering and Cardiovascular Risk in Adolescents

Start: Sep 2011Est. completion: Jan 2012
N/ACompleted
NCT04686812Angeles TherapeuticsWorksite health promotion program

Worksite Health Promotion Intervention to Promote Healthy Habits Among Workers From Mexican Companies

Start: Jun 2009Est. completion: Jun 20112,002 patients
N/ACompleted
NCT00882336AstraZenecaEuropean Study of Cardiovascular Risk

European Study of Cardiovascular Risk

Start: May 2009Est. completion: Oct 20097,200 patients
N/ACompleted
NCT00848380AstraZenecaManagement of Cardiovascular Risk Factors

Management of Cardiovascular Risk Factors

Start: Feb 2009Est. completion: Dec 20091,492 patients
N/ACompleted
NCT00486993Heidelberg PharmaDietary and nutritional modification

Cardiovascular Risk Factors in an Ambulatory Urban Patient Population

Start: May 2006Est. completion: Jul 201418,287 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.